Prostacyclin in sepsis: a systematic review.
According to current literature, infective processes greatly modify both vascular hemodynamics and anti-oxidant properties of affected tissues, causing a change in homeostasis that regulates the correct functioning of all cells responsible for the physiological and metabolic balance of various organs. As a consequence, the response to the infection that has caused the change is also likely to be weaker and, in the case of septic shock, ineffective. In this review, we will take into consideration these mechanisms and then focus on a group of vasodilator drugs (prostacyclin and its analogs) which, though have been used for over 20 years mainly to treat obstructive vascular diseases, have such hemodynamic and anti-inflammatory properties which prevent homeostatic changes. It is obvious that prostacyclin does not definitively have anti-infective characteristics; however, in association with anti-infective drugs (antibiotics, etc.), the effectiveness of the latter appears improved, at least in some circumstances. Similarly, the fact that prostacyclin and its analogs have a cytoprotective effect on the liver and reduce the ischemia-reperfusion damage following liver transplant is not a novelty and evidence that they improve hepatic hemodynamics suggests their use in those pathologies characterized by possible reduced perfusion or ascertained ischemia of the liver.
Zardi
E M
EM
Area of Internal Medicine and Immunology, University Campus Bio-Medico, Rome, Italy. e.zardi@unicampus.it
Zardi
D M
DM
Dobrina
A
A
Afeltra
A
A
D000818:Animals; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D015427:Reperfusion Injury; D018805:Sepsis / Q000378:metabolism*; D013152:Splanchnic Circulation / Q000187:drug effects
D011464:Epoprostenol